Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma - Scorecard - MDSpire
Advertisement
Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma
Clinical Scorecard: Evaluating the Role of Ki-67 Expression as a Predictor of Pathological Response to Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
At a Glance
Category
Detail
Condition
Lung Squamous Cell Carcinoma
Key Mechanisms
Ki-67 expression as a biomarker for predicting pathological response
Target Population
Patients with stage IIIA–IIIB lung squamous cell carcinoma
Care Setting
Neoadjuvant therapy followed by surgical resection
Key Highlights
MPR/pCR achieved in 56.2% of patients (77/137)
Optimal Ki-67 cutoff identified at 55% with AUC = 0.785
High Ki-67 (≥55%) linked to significantly higher MPR/pCR rates (69.6% vs. 27.9%)
Ki-67 and smoking status are independent predictors of MPR/pCR
PD-L1 expression showed no significant association with MPR/pCR
Guideline-Based Recommendations
Diagnosis
Assess Ki-67 expression via immunohistochemistry in patients undergoing neoadjuvant therapy
Management
Consider Ki-67 levels when evaluating potential response to neoadjuvant chemoimmunotherapy
Monitoring & Follow-up
Monitor Ki-67 expression as part of treatment response evaluation
Risks
Potential for misclassification of patients based on Ki-67 levels alone
Patient & Prescribing Data
Patients with histologically confirmed stage IIIA–IIIB lung SCC
Neoadjuvant PD-1 inhibitors plus platinum-based chemotherapy followed by surgery
Clinical Best Practices
Utilize Ki-67 as a predictive biomarker in clinical decision-making for neoadjuvant therapy
Ensure comprehensive assessment of patient history, including smoking status
